Biotest AG

Biotest AG is a specialist provider of plasma-derived therapeutics and biopharmaceutical medicines based in Dreieich, Germany. The company operates across clinical immunology, haematology, and intensive care medicine, developing and manufacturing plasma proteins including clotting factors, immunoglobulins, albumin, and monoclonal antibodies. Biotest is the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins. The company was acquired by Grifols S.A. in April 2022 and now operates as a subsidiary within the Grifols Group, leveraging Grifols' global distribution capabilities while maintaining independent R&D and manufacturing operations. Biotest's product portfolio includes Intratect (immunoglobulin for secondary immune deficiencies and autoimmune neurological conditions), Yimmugo (FDA-approved in June 2024 for primary immunodeficiencies), and pipeline candidates including trimodulin (BT-588) for severe community-acquired pneumonia and fibrinogen concentrate (BT-524) for acquired fibrinogen deficiency. The company operates 37 plasma collection centres across Europe and manufacturing exclusively in Germany, with significant recent expansion of plasma collection infrastructure including 13 dedicated centres in Germany.